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Nanoparticles have been deeply studied as carrier for imaging and drug delivery, but their clinical 
application still remains an unrealized dream. Nanodrugs have the potential to address some 
important concerns related to bioavailability, tissue penetration, circulation time, toxicity and 
protection from degradation/sequestration [1] since their size, surface charge and geometry may 
affect pharmacokinetic profiles [2]. Indeed, nanoparticles could be exploited to allow of the 
crossing of drugs through physiological barriers, to reach targeted sites, and to increase drugs half 
life and efficacy while reducing doses. Several nanoparticles, such as metal oxides, quantum dots, 
carbon nanotubes, liposomes and polymers, have been investigated at the preclinical level [3]. 
However, only few of them have been clinically approved since toxicity, immunogenicity and 
sequestration by liver reticulo-endothelial system still remain the main hindrances to translation to 
the clinic. [4].  Therefore, although great clinical appealing, nanotechnology are still poorly being 
translated into clinical practice [5].  
In this scenario, protein-based nanocages  represent a particular class of nanomaterials that may 
address many of these concerns [6]. The charm of protein-based nanotechnology relies on the fact 
that proteins often have minimal toxicity and immunogenicity, and can be easily degraded by the 
organism once they have carried out their function [7]. Protein caged nanoparticles are constituted 
by self-assembling protein subunits generally arranged in a hollow structure, which displays 
symmetrical repetitive elements; caged architectures could be constituted by unique or multiple 
proteins that are the building block of the nanoparticles [1, 7]. Protein monomers could be produced 
in living hosts (i.e. E. coli, plants, mammalian cells, yeast and baculoviruses) and genetically 
modified inserting surface functionalities by DNA-recombinant technology, allowing a fine control 
of surface charge, ligand display, nanoparticles stability and active molecule encapsulation [7]. 
Besides, the nanocage building blocks are arranged to form a shell, which possess three distinct 
contact point: the interior, the interface and the exterior. These regions can be chemically or 
genetically engineered to insert pharmaceuticals and/or probes or to shape various and more ordered 
functionalities [1]. The simultaneous presence of these three region of interface in one single cage 
allows the contemporary display of different capabilities, enabling the realization of multifunctional 
nanoparticles, such as nano-probes for imaging detection of lesions combined with drug delivery 
devices for therapeutic purposes. Unlike other protein-based nanomaterials, protein nanocages 
possess some other unique features very appealing from the clinical point of view: 1) their uniform 
cage allow the precise control of the amount of encapsulated drugs/probes, which is crucial in 
define drug dosage; 2) avoidance of macromolecular aggregation of the nanoparticle; 3) stability in 
physiological environment as a result of their protein nature, with subsequent increased circulation 
time, protection of the cargo molecule from degradation and improved bioavailability [1]. 
Moreover, protein nanoparticles are resistant to a wide range of pH and temperature, so they are 
compatible with the chemical environment required for modifications [8]. Furthermore their 
capability to disassemble the quaternary structure in response of a precise stimulus is particularly 
useful to drugs and/or probes encapsulation [9]. Finally, due to their reduced size, protein cages are 
able to escape from the reticulo-endothelial system increasing their accumulation to the target site 
[10]. 
These features are strongly appealing from the clinical point of view since the development of a 
smart drug delivery system is a primary challenge to face diseases of great impact, such as cancer or 
infectious diseases where current treatments exhibit some major limitations mostly related to their 
poor pharmacokinetic profile [11]. Indeed, the development of a specific drug delivery device able 
to increase drug efficacy reducing side-effects could be useful to improve patient compliance.  
Protein-based nanoparticles possess other peculiar characteristics depending on the type of protein 
that constitutes the scaffold, which could find application in clinics.  Among protein nanocages we 
can include human protein such as Vault particles, Heat Shock Proteins and ferritins, but also viral 
protein like those which form the viral capsid [12].  
The latter are constituted by one many viral capsid proteins. Although they include a wide variety 
of sizes and morphologies with well-defined geometries (icosahedral or helical), capsids possess 
uniform shape and robust protein shell, suitable for biological and chemical conjugation and stable 
over a wide range of pH and temperatures [1, 8]. Despite virus particles have found wide 
application in gene therapy and vaccines, they have been also used as drug delivery devices [8]. A 
virus particle functionalized with folic acid has been used to mediate the delivery of doxorubicin to 
ovary cancer cells with a significant increase in drug cellular uptake and subsequent higher efficacy 
[1]. Neverthless viral protein are quite difficult to produce in bulk strongly limiting their biomedical 
application, and some issues about the host immunological response still have to be addressed [1, 
13]. 
Vault particles represent an extremely interesting and versatile solution with high potential both as 
drug delivery device, both as imaging agent because: 1) they have a spacious internal volume, 
which is suitable for the encapsulation of bioactive molecules; 2) they are constituted by naturally 
occurring amino-acids sequences with no declared immunogenicity and toxicity; 3) they are easy to 
genetically modify; and 4) they are arranged in a dynamic cage that can disassemble into two halves 
in response to a lowering of the pH [14]. At present, some studies have been performed using this 
particle as drug delivery device, while have not yet found application as imaging agents [14]. 
Heat Shock Protein (sHsp) has the external size of sHsp is 12 nm in diameter and is constituted by 
24 subunits arranged to outline the internal cavity of  6.5 nm in diameter. The sHsp architecture 
displays large size pores of about 3 nm in diameter able to mediate the free exchange of cargo 
between the inside and the outside [1]. As other caged proteins, it is stable until 70 °C and in a pH 
range between 5 to 11, implying its resistance to the harsh conditions under which chemical 
modifications take place [15]. Moreover, since the sHsp cage does not contain cysteine residues, 
they could be introduced by site-directed mutagenesis to allow further attachment of bioactive 
molecules [15]. Also, lysine residues have been used for chemical conjugation, while the genetic 
fusion with melanoma and lymphocyte cell-specific targeting moieties has been exploited to deliver 
doxorubicin [16]. But in our opinion, the most promising protein based-nanocage is represented by 
ferritin. Ferritin nanoparticles can be easily produced by DNA recombinant technology in host 
organisms with good yields [17]. They possess a 8 nm central cavity loadable with transition 
metals, drugs, fluorescent molecules or other contrast agents with high efficiency [18]. Moreover, 
the protein shell of ferritins has been be easily modified via either chemical or genetic modifications 
to introduce functionalities, such as targeting moieties, drugs, quenchers, dyes, contrast agents and 
even siRNAs [19]. Ferritin nanocages constituted by 24-mer of H subunits have already been 
largely explored for cytotoxic drug delivery into cancer sites with encouraging results [20]. The 
natural tumor homing of H-ferritin nanocages due to specific recognition of the transferrin receptor 
1 (TfR-1), which is overexpressed several cancer subtypes, ensured the high efficacy otained with 
these nanoparticles [20]. Ferritin have also been reported as a good nanovector for nuclear delivery 
of drug exploiting a physiological mechanism of nuclear translocation [17]. In this case, a 
Doxorubicin-loaded H-Ferritin is able to mediate DOX self-triggered nuclear translocation 
increasing drug efficacy. The sum of all these data makes ferritin the most appealing protein 
nanocage, and also the candidate of choice for the future applications in the field of nanomedicine. 
Indeed, a lot of work has already been done for the development of ferritin-based devices for MRI, 
optical imaging, hyperthermal therapy and drug delivery. As mentioned above, promising results 
have been obtained allowing the development of multifunctional devices for imaging and therapy. 
Despite this, much work has to be done to enhance the knowledge about (1) the fate of ferritin and 
its derivatives after systemic injection, (2) their toxicity in off-target organs, (3) the real impact if 
immunogenicity and toxicity of ferritin derivatives for further clinical translation. Although further 
research is still strongly required, ferritin nanoparticles are undoubtedly the protein-based 
nanocages with the translational highest potential for development of smart imaging and therapeutic 
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